Achieve Life Sciences Inc - Asset Resilience Ratio
Achieve Life Sciences Inc (ACHV) has an Asset Resilience Ratio of 3.60% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ACHV working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1996–2025)
This chart shows how Achieve Life Sciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Achieve Life Sciences Inc (ACHV) total assets.
Liquid Assets Composition Over Time
This chart breaks down Achieve Life Sciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Achieve Life Sciences Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.19 Million | 3.6% |
| Total Liquid Assets | $1.19 Million | 3.60% |
Asset Resilience Insights
- Limited Liquidity: Achieve Life Sciences Inc maintains only 3.60% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Achieve Life Sciences Inc Industry Peers by Asset Resilience Ratio
Compare Achieve Life Sciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Enliven Therapeutics Inc.
NASDAQ:ELVN |
Biotechnology | 83.46% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
Annual Asset Resilience Ratio for Achieve Life Sciences Inc (1996–2025)
The table below shows the annual Asset Resilience Ratio data for Achieve Life Sciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.03% | $15.47 Million | $41.79 Million | -18.90pp |
| 2024-12-31 | 55.93% | $21.61 Million | $38.63 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $19.37 Million | -- |
| 2019-12-31 | 0.24% | $50.00K | $21.08 Million | -26.43pp |
| 2018-12-31 | 26.67% | $5.09 Million | $19.08 Million | +24.42pp |
| 2017-12-31 | 2.24% | $222.00K | $9.89 Million | -35.00pp |
| 2016-12-31 | 37.24% | $10.23 Million | $27.47 Million | +1.38pp |
| 2015-12-31 | 35.86% | $20.88 Million | $58.21 Million | +1.83pp |
| 2014-12-31 | 34.04% | $19.16 Million | $56.29 Million | -10.19pp |
| 2013-12-31 | 44.23% | $24.63 Million | $55.69 Million | -25.65pp |
| 2012-12-31 | 69.87% | $57.31 Million | $82.02 Million | +16.34pp |
| 2011-12-31 | 53.53% | $36.41 Million | $68.02 Million | -14.95pp |
| 2010-12-31 | 68.48% | $61.57 Million | $89.92 Million | +64.83pp |
| 2009-12-31 | 3.65% | $2.52 Million | $68.98 Million | -36.18pp |
| 2008-12-31 | 39.83% | $5.89 Million | $14.79 Million | -21.30pp |
| 2007-12-31 | 61.14% | $27.66 Million | $45.25 Million | +28.28pp |
| 2006-12-31 | 32.86% | $22.51 Million | $68.49 Million | -56.48pp |
| 2004-12-31 | 89.34% | $20.16 Million | $22.57 Million | +5.70pp |
| 2003-12-31 | 83.63% | $17.95 Million | $21.47 Million | -5.34pp |
| 2002-12-31 | 88.97% | $15.96 Million | $17.93 Million | -3.50pp |
| 2001-12-31 | 92.47% | $14.67 Million | $15.86 Million | +45.19pp |
| 2000-12-31 | 47.28% | $6.77 Million | $14.31 Million | -13.00pp |
| 1999-12-31 | 60.28% | $10.91 Million | $18.10 Million | -6.48pp |
| 1996-12-31 | 66.75% | $17.89 Million | $26.80 Million | -- |
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more